Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aditxt Inc
(NQ:
ADTX
)
0.6421
+0.0631 (+10.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aditxt Inc
< Previous
1
2
3
4
5
6
7
Next >
Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO
January 10, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms Subsidiary with Focus on Immune Modulation Therapies
January 03, 2023
Via
Investor Brand Network
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
January 03, 2023
From
Aditxt, Inc.
Via
Business Wire
Research Explains Why MS Patients Benefit from Stem Cell Transplants
November 16, 2022
Via
Investor Brand Network
Why Food Allergies May Be Increasing
October 28, 2022
Via
Investor Brand Network
Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis
December 28, 2022
Via
Investor Brand Network
Researchers Look to AI to Improve Organ Transplant Processes
November 30, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports
November 28, 2022
Via
Investor Brand Network
Exposures
COVID-19
Department of Defense Awards Scientists at University of Buffalo $4M Grant to Study Concussion Treatment
November 23, 2022
Via
Investor Brand Network
Genes That Saved People from Bubonic Plague Linked to Autoimmune Conditions Today
November 11, 2022
Via
Investor Brand Network
Research Finds That Stem Cells Reduce Lung Transplant Rejection Rates
November 03, 2022
Via
Investor Brand Network
Study Finds Livers with a Cumulative Age of 100 Years
October 21, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Key Milestone in Advancing Adimune(TM) Program
October 21, 2022
Via
Investor Brand Network
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials
October 21, 2022
From
Aditxt, Inc.
Via
Business Wire
Allergies: How They Occur and Why They Sometimes Disappear
October 14, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Publication of Innovative Mathematical Model
October 12, 2022
Via
Investor Brand Network
Exposures
COVID-19
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection
October 12, 2022
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Featured in FedEx Video Presentation
October 07, 2022
Via
Investor Brand Network
Exposures
COVID-19
People with Autoimmune Disorders More Likely to Suffer Post-Heart Attack Complications, Study Finds
October 07, 2022
Via
Investor Brand Network
FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health
October 07, 2022
From
Aditxt, Inc.
Via
Business Wire
Transplant Team at UW Medicine Completes Groundbreaking Surgery
October 03, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
September 29, 2022
Via
Investor Brand Network
Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements
September 29, 2022
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Corporate Update Following Reverse Stock Split, Closing of $20M Public Offering
September 27, 2022
Via
Investor Brand Network
Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering
September 27, 2022
From
Aditxt, Inc.
Via
Business Wire
UBC Scientists Believe Insulin Tablet to Treat Diabetes May Soon Be Available
September 26, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on Recently Announced $20M Public Offering
September 21, 2022
Via
Investor Brand Network
Aditxt Announces Closing of $20.0 Million Public Offering
September 20, 2022
From
Aditxt, Inc.
Via
Business Wire
The US Reaches One Million Organ Transplants
September 16, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Pricing of Public Offering
September 16, 2022
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.